03:46 AM EDT, 06/03/2024 (MT Newswires) -- BioCryst Pharmaceuticals ( BCRX ) said Sunday an analysis showed that six patients with hereditary angioedema experienced a reduction in monthly attacks while taking oral, once-daily Orladeyo.

BioCryst said the data, presented at a conference in Spain, shows "clinically relevant evidence" that the drug, also known as berotralstat, can "reduce the frequency and duration of episodes" among hereditary angioedema patients who have normal C1-inhibitor level and function.

Hereditary angioedema is a disorder that results in recurrent episodes of severe swelling.

Price: 6.47, Change: +0.01, Percent Change: +0.15